<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660827</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 302</org_study_id>
    <nct_id>NCT02660827</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes</brief_title>
  <official_title>Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in pediatric
      subjects with type 1 diabetes on insulin pump therapy. The purpose of this study is to
      demonstrate that the closed loop algorithm is safe as part of the overall system, and to
      assess the PLGM feature in 7-13 years old subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will proceed as follows:

      Run-in Period - General:

      A total of up to 200 subjects (age 2-13) will be enrolled at up to 15 investigational centers
      (14 in the US, 1 EMEA) in order to reach 120 subjects who will complete the HCL study.

      Study Period - At Home:

      Following the two week run-in period using the Study Pump (670G), all subjects (age 2-13)
      will participate in a 3-month study period.

      Study Period - Hotel Study Subjects (age 7-13) will participate in a Hotel study (6 days, 5
      nights), with the remainder of the study period to be spent at home. Subjects 2-6 years of
      age are not required to participate in a hotel study. Instead, they will participate in an
      out-of-home study for 5 consecutive days, 4-6 hours per day.

      Continued Access Program Subjects will be given the opportunity to extend use of their study
      devices for a period of 2 years. If subjects choose to participate in the continuation
      period, they will retain the study devices at the end of study period visit or receive them
      back in the event they have been returned to study staff already.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 18, 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">November 28, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Age 7-13 Years Old Subjects Change in A1C</measure>
    <time_frame>Baseline and end of 3-month treatment period</time_frame>
    <description>Descriptive analysis of change in A1C from baseline to end of 3-month treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age 7-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 7-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (&gt; 180 mg/dL)</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>mean change in % of time in hyperglycemia (&gt; 180 mg/dL) from baseline to 3 months treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 7-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (&lt;70 mg/dL)</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>mean change in % of time in hypoglycemia (&lt; 70 mg/dL) from baseline to 3 months treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 7-13 Years Old - Number of Severe Hypoglycemic Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of severe hypoglycemic events occurred during 3-month treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 7-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST &lt;=65 mg/dL</measure>
    <time_frame>Up to 12 hours after the start of PLGM period</time_frame>
    <description>Event rate without Hypoglycemia at YSI-FST &lt;=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST &lt;= 65mg/dL during in-clinic procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 2-6 Years Old Subjects Change in A1C</measure>
    <time_frame>Baseline and end of 3-month treatment period</time_frame>
    <description>Descriptive analysis of change in A1C from baseline to end of 3-month treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 2-6 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 2-6 Years Old Subjects Mean Change in % of Time in Hyperglycemia (&gt; 180 mg/dL)</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>mean change in % of time in hyperglycemia (&gt; 180 mg/dL) from baseline to 3 months treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 2-6 Years Old Subjects Mean Change in % of Time in Hypoglycemia (&lt;70 mg/dL)</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>mean change in % of time in hypoglycemia (&lt; 70 mg/dL) from baseline to 3 months treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 2-6 Years Old - Number of Severe Hypoglycemic Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of severe hypoglycemic events occurred during 3-month treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age 2-6 Years Old - Number of Diabetic Ketoacidosis (DKA) Event</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month treatment period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Hybrid closed loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin Pump</intervention_name>
    <description>Closed Loop Algorithm</description>
    <arm_group_label>Hybrid closed loop</arm_group_label>
    <other_name>MMT-670G</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General Inclusion Criteria

          1. Subject is age 2-13 years at time of screening

          2. Subject has a clinical diagnosis of type 1 diabetes for 1 year or more as determined
             via medical record or source documentation by an individual qualified to make a
             medical diagnosis

          3. Subject age 2-6 years has a clinical diagnosis of type 1 diabetes for 3 months or more
             as determined via medical record or source documentation by an individual qualified to
             make a medical diagnosis

             Study-specific inclusion criteria

          4. Subject must have a minimum daily insulin requirement (Total Daily Dose) of greater
             than or equal to 8 units

          5. Subjects 7-13: Subjects and their parent(s)/guardian(s) are willing to participate in
             an overnight visit at the end of the run-in period.

          6. Subject 7-13 years of age and their parent(s)/guardian(s) are willing to participate
             in a hotel study for the specified duration of hotel stay.

          7. Subject 2-6 years of age and their parent(s)/guardian(s) are willing to participate in
             an extended visit during the study period to perform Frequent Sample Testing.

          8. Subject must have companion 18 years or older who will sleep in the same dwelling
             place every night during the study period. This requirement may be verified by subject
             report at screening visit.

          9. Subject is willing to perform ≥ 4 finger stick blood glucose measurements daily

         10. Subject is willing to perform required sensor calibrations

         11. Subject is willing to wear the system continuously throughout the study

         12. Subject has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by
             Central Lab) at time of screening visit Note: All HbA1C blood specimens will be sent
             to and tested by a NGSP certified Central Laboratory. A1C testing must follow National
             Glycohemoglobin Standardization Program (NGSP) standards.

         13. Subject has TSH in the normal range OR if the TSH is out of normal reference range the
             Free T3 is below or within the lab's reference range and Free T4 is within the normal
             reference range.

         14. Subject 7 -13 years of age has had pump therapy for greater than 6 months prior to
             screening (with or without CGM experience)

         15. Subject 2-6 years of age has had pump therapy for greater than 90 days prior to
             screening (with or without CGM experience)

         16. Subjects and their parent(s)/guardian(s) are willing to upload data from the study
             pump; must have Internet access and a computer system that meets the requirements for
             uploading the study pump

         17. If subject has celiac disease, it has been adequately treated as determined by the
             investigator

         18. Subjects and their parent(s)/guardian(s) are willing to take one of the following
             insulins and can financially support the use of either of the 2 insulin preparations
             throughout the course of the study (i.e. co-payments for insulin with insurance or
             able to pay full amount)

               -  Humalog® (insulin lispro injection)

               -  NovoLog® (insulin aspart)

         19. Subjects and their parent(s)/guardian(s)/companions must be able to speak and be
             literate in English as verified by the investigator

        Exclusion Criteria:

          1. Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in
             any the following during the 6 months prior to screening:

               1. Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)

               2. Coma

               3. Seizures

          2. Subject is unable to tolerate tape adhesive in the area of sensor placement

          3. Subject has any unresolved adverse skin condition in the area of sensor placement
             (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)

          4. Females who are sexually active and able to conceive will be excluded if they are not
             using an effective method of contraception and do not agree to continue using an
             effective method of contraception for the duration of the study as determined by
             investigator.

          5. Subject has a cardiovascular condition which the investigator determines should
             exclude the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy

          6. Subject is being treated for hyperthyroidism at time of screening

          7. Subject has diagnosis of adrenal insufficiency

          8. Subject 7-13 years of age has had DKA in the 6 months prior to screening visit.

          9. Subject 2-6 years of age has had DKA in the 3 months prior to screening visit

         10. Subject has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8
             weeks from time of screening visit, or plans to take any oral, injectable, or IV
             glucocorticoids during the course of the study

         11. Subject is actively participating in an investigational study (drug or device) wherein
             he/she has received treatment from an investigational study drug or investigational
             study device in the last 2 weeks

         12. Subject 7-13 years of age has been hospitalized or has visited the ER in the 6 months
             prior to screening resulting in a primary diagnosis of uncontrolled diabetes

         13. Subject 2-6 years of age has been hospitalized or has visited the ER in the 3 months
             prior to screening resulting in a primary diagnosis of uncontrolled diabetes

         14. Subject is currently abusing illicit drugs

         15. Subject is currently abusing marijuana.

         16. Subject is currently abusing prescription drugs

         17. Subject is currently abusing alcohol

         18. Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other
             GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time
             of screening

         19. Subject has a history of visual impairment which would not allow subject to
             participate in the study and perform all study procedures safely, as determined by the
             investigator

         20. Subject has elective surgery planned that requires general anesthesia during the
             course of the study

         21. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell
             transfusion or erythropoietin within 3 months prior to time of screening

         22. Subject plans to receive red blood cell transfusion or erythropoietin over the course
             of study participation

         23. Subject diagnosed with current eating disorder such as anorexia or bulimia

         24. Subject has been diagnosed with chronic kidney disease that results in chronic anemia

         25. Subject has a hematocrit that is below the normal reference range of lab used.

         26. Subject is on dialysis

         27. Subject has serum creatinine of &gt;2 mg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida - USF Health</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 16, 2016</study_first_submitted>
  <study_first_submitted_qc>January 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <results_first_submitted>October 22, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02660827/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02660827/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two age groups study: 7-13 Years old and 2-6 Years old</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects Wearing MMT-670G Insulin Pump</title>
          <description>Subjects wearing MMT- 670G insulin pump</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>7-13 Years Old Age Group</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2-6 Years Old Age Group</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature; 2-6 years old subjects wearing MMT-670G insulin pump.</population>
      <group_list>
        <group group_id="B1">
          <title>7-13 Years Old Subjects Wearing MMT-670G Insulin Pump</title>
          <description>7-13 years old subjects wearing MMT- 670G insulin pump</description>
        </group>
        <group group_id="B2">
          <title>2-6 Years Old Subjects Wearing MMT-670G Insulin Pump</title>
          <description>2-6 years old subjects wearing MMT- 670G insulin pump</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" spread="1.8"/>
                    <measurement group_id="B2" value="4.6" spread="1.4"/>
                    <measurement group_id="B3" value="8.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m2)</title>
          <population>One Subject in 7-13 Years age group height and weight were not measured at enrollment.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="104"/>
                    <count group_id="B2" value="46"/>
                    <count group_id="B3" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.1" spread="4.3"/>
                    <measurement group_id="B2" value="16.7" spread="1.7"/>
                    <measurement group_id="B3" value="18.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Age 7-13 Years Old Subjects Change in A1C</title>
        <description>Descriptive analysis of change in A1C from baseline to end of 3-month treatment period</description>
        <time_frame>Baseline and end of 3-month treatment period</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old Subjects Change in A1C</title>
          <description>Descriptive analysis of change in A1C from baseline to end of 3-month treatment period</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 7-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)</title>
        <description>mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months treatment period</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)</title>
          <description>mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months treatment period</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>Percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.76" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 7-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (&gt; 180 mg/dL)</title>
        <description>mean change in % of time in hyperglycemia (&gt; 180 mg/dL) from baseline to 3 months treatment period</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old Subjects Mean Change in % of Time in Hyperglycemia (&gt; 180 mg/dL)</title>
          <description>mean change in % of time in hyperglycemia (&gt; 180 mg/dL) from baseline to 3 months treatment period</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>Percent of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.11" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 7-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (&lt;70 mg/dL)</title>
        <description>mean change in % of time in hypoglycemia (&lt; 70 mg/dL) from baseline to 3 months treatment period</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old Subjects Mean Change in % of Time in Hypoglycemia (&lt;70 mg/dL)</title>
          <description>mean change in % of time in hypoglycemia (&lt; 70 mg/dL) from baseline to 3 months treatment period</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>percent of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 7-13 Years Old - Number of Severe Hypoglycemic Event</title>
        <description>Number of severe hypoglycemic events occurred during 3-month treatment period.</description>
        <time_frame>3 months</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old - Number of Severe Hypoglycemic Event</title>
          <description>Number of severe hypoglycemic events occurred during 3-month treatment period.</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 7-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event</title>
        <description>Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month treatment period.</description>
        <time_frame>3 months</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old - Number of Diabetic Ketoacidosis (DKA) Event</title>
          <description>Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month treatment period.</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST &lt;=65 mg/dL</title>
        <description>Event rate without Hypoglycemia at YSI-FST &lt;=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST &lt;= 65mg/dL during in-clinic procedures.</description>
        <time_frame>Up to 12 hours after the start of PLGM period</time_frame>
        <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 7-13 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 7-13 Years Old Subjects PLGM Performance - Event Rate Without Hypoglycemia at YSI-FST &lt;=65 mg/dL</title>
          <description>Event rate without Hypoglycemia at YSI-FST &lt;=65 mg/dL among 105 subjects who underwent the PLGM experiments. The event rate without hypoglycemia is the number of experiments without hypoglycemia/total number of experiments and hypoglycemic events are defined based on the occurrence of 2 or more continuous YSI-FST &lt;= 65mg/dL during in-clinic procedures.</description>
          <population>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</population>
          <units>percentage of total experiments</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 2-6 Years Old Subjects Change in A1C</title>
        <description>Descriptive analysis of change in A1C from baseline to end of 3-month treatment period</description>
        <time_frame>Baseline and end of 3-month treatment period</time_frame>
        <population>2-6 years old subjects wearing MMT-670G insulin pump, 2 subjects End of Study A1C not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2-6 Years Old Wearing MMT-670G Insulin Pump</title>
            <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 2-6 Years Old Subjects Change in A1C</title>
          <description>Descriptive analysis of change in A1C from baseline to end of 3-month treatment period</description>
          <population>2-6 years old subjects wearing MMT-670G insulin pump, 2 subjects End of Study A1C not collected.</population>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 2-6 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)</title>
        <description>mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months treatment period</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2-6 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 2-6 Years Old Subjects Mean Change in % of Time in Euglycemia (70-180 mg/dL)</title>
          <description>mean change in % of time in Euglycemia (70-180 mg/dL) from baseline to 3 months treatment period</description>
          <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
          <units>Percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 2-6 Years Old Subjects Mean Change in % of Time in Hyperglycemia (&gt; 180 mg/dL)</title>
        <description>mean change in % of time in hyperglycemia (&gt; 180 mg/dL) from baseline to 3 months treatment period</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2-6 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 2-6 Years Old Subjects Mean Change in % of Time in Hyperglycemia (&gt; 180 mg/dL)</title>
          <description>mean change in % of time in hyperglycemia (&gt; 180 mg/dL) from baseline to 3 months treatment period</description>
          <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
          <units>Percent of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.03" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 2-6 Years Old Subjects Mean Change in % of Time in Hypoglycemia (&lt;70 mg/dL)</title>
        <description>mean change in % of time in hypoglycemia (&lt; 70 mg/dL) from baseline to 3 months treatment period</description>
        <time_frame>baseline and 3 months</time_frame>
        <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2-6 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 2-6 Years Old Subjects Mean Change in % of Time in Hypoglycemia (&lt;70 mg/dL)</title>
          <description>mean change in % of time in hypoglycemia (&lt; 70 mg/dL) from baseline to 3 months treatment period</description>
          <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
          <units>percent of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 2-6 Years Old - Number of Severe Hypoglycemic Event</title>
        <description>Number of severe hypoglycemic events occurred during 3-month treatment period.</description>
        <time_frame>3 months</time_frame>
        <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2-6 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 2-6 Years Old - Number of Severe Hypoglycemic Event</title>
          <description>Number of severe hypoglycemic events occurred during 3-month treatment period.</description>
          <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Age 2-6 Years Old - Number of Diabetic Ketoacidosis (DKA) Event</title>
        <description>Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month treatment period.</description>
        <time_frame>3 months</time_frame>
        <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
        <group_list>
          <group group_id="O1">
            <title>Age 2-6 Years Old Wearing the MMT-670G Insulin Pump</title>
            <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Age 2-6 Years Old - Number of Diabetic Ketoacidosis (DKA) Event</title>
          <description>Number of Diabetic Ketoacidosis (DKA) events occurred during 3-month treatment period.</description>
          <population>2-6 years old subjects wearing MMT-670G insulin pump.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>7-13 Years Old Wearing MMT-670G Insulin Pump</title>
          <description>7-13 years old subjects wearing MMT-670G insulin pump, participating in clinical evaluation of the suspend before low feature.</description>
        </group>
        <group group_id="E2">
          <title>2-6 Years Old Wearing MMT-670G Insulin Pump</title>
          <description>2-6 years old subjects wearing MMT-670G insulin pump.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dacryocanaliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Torus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood ketone body increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="37" subjects_at_risk="105"/>
                <counts group_id="E2" events="65" subjects_affected="19" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Lipoatrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vivian Chen, Statistician</name_or_title>
      <organization>Medtronic Minimed</organization>
      <phone>8185763309</phone>
      <email>vivian.chen@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

